Amman -19 December 2013
Hikma Pharmaceutical founder and chairman, Mr. Samih Darwazah, was recently selected as the First on the Emerging Markets Leaders of the Scrip 100 list.
Samih Darwazah founded Hikma Pharmaceuticals in 1978 after receiving his Masters degree in Industrial Pharmacy form St. Louis College of Pharmacy, Missouri. Hikma Pharmaceuticals is a leading pharmaceutical firm devoted to developing, manufacturing and marketing quality medication.
The Scrip 100 list recognizes company heads that are shaping the future of pharma in their respective countries; it also looks for those that are leading the industry through this transformative period of time. It includes in addition to Mr. Samih Darwazah a number of significant emerging market pharmaceutical leaders such as Bill and Melinda Gates for the Gates foundation, Takeda's Head of Commercial Operations, and the CEO of Samsung Biologics.
The Scrip 100 is a list of the top 100 leaders in the pharmaceutical business compiled by the Scrip editorial team. The top 100 leaders selected include philanthropists, regulators and company heads. The final decision on inclusion came after much discussion and debate that considered a global view of the biopharmaceutical industries.
-Ends-
About Hikma
Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the MENA region, where it is a market leader, the United States and Europe. .
For news and other information, please visit www.hikma.com
HIKMA Pharmaceuticals
Name: Hana Ramadan, Maha Hammad
Email: hramadan@hikma.com, mhammad@hikma.com
Tel: Hana Ramadan (+962) 6 5802900 Ext. 313, 356
VARCC-Arabian Communications
Name: Sara Haddadin
Email: sara.haddadin@varcc.com
Tel: (+962) 6 5547161
Fax:(+962) 6 5547162
© Press Release 2013
